The role of circulating thrombospondin-1 in patients with precapillary pulmonary hypertension

Respiratory Research

Volumn 17, Issue 1, 2016, Pages

  Kaiser, Ralf ^a   Frantz, Christian ^b   Bals, Robert ^a   Wilkens, Heinrike ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Hôpitaux Robert Schuman Zithaklinik   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIN; THROMBOSPONDIN 1; ENDOTHELIN 1; THROMBOSPONDIN-1, HUMAN;

ADULT; ADVERSE OUTCOME; ARTICLE; CAUSE OF DEATH; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG RESISTANCE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SURVIVAL; AGED; ARTERIAL PRESSURE; BLOOD; CASE CONTROL STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PULMONARY ARTERY; RISK FACTOR; TIME FACTOR; UPREGULATION; VASCULAR RESISTANCE;

ADULT; AGED; ARTERIAL PRESSURE; BIOMARKERS; CARDIAC CATHETERIZATION; CASE-CONTROL STUDIES; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY ARTERY; RISK FACTORS; THROMBOSPONDIN 1; TIME FACTORS; UP-REGULATION; VASCULAR RESISTANCE;

EID: 84979658592     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-016-0412-x     Document Type: Article

References (24)

1. Bréchot N, Gomez E, Bignon M, Khallou-Laschet J, Dussiot M, Cazes A, et al. Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. PLoS One [Internet]. 2008;3:e3950. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2597179&tool=pmcentrez&rendertype=abstract. Accessed 26 July 2016.
2. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A, et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005;111:2935-42.
3. Laderoute KR, Alarcon RM, Brody MD, Calaoagan JM, Chen EY, Knapp a M, et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res [Internet]. 2000;6:2941-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10914744. Accessed 26 July 2016.
4. Ahamed J, Janczak CA, Wittkowski KM, Coller BS. In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring- and shear-dependent activation of platelet-derived TGF-beta1. PLoS One [Internet]. 2009;4:e6608. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2719874&tool=pmcentrez&rendertype=abstract. Accessed 26 July 2016.
5. Jaffe E a, Ruggiero JT, Falcone DJ. Monocytes and macrophages synthesize and secrete thrombospondin. Blood [Internet]. 1985;65:79-84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3965054. Accessed 26 July 2016.
6. Kobayashi S, Yamamoto T. The molecular biologic study of the expression of thrombospondin in vascular smooth muscle cells and mesangial cells. J Diabet Complications UNITED STATES. 1991;5:121-3.
7. Mosher DF, Doyle MJ, Jaffe EA. Synthesis and secretion of thrombospondin by cultured human endothelial cells. J Cell Biol [Internet]. 1982;93:343-8. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2112841&tool=pmcentrez&rendertype=abstract. Accessed 26 July 2016.
8. Sezaki S, Hirohata S, Iwabu A, Nakamura K, Toeda K, Miyoshi T, et al. Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood, NJ) [Internet]. 2005;230:621-30. Department of Medicine and Medical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan. http://www.ncbi.nlm.nih.gov/pubmed/16179730.
9. Kaur S, Soto-Pantoja DR, Stein EV, Liu C, Elkahloun AG, Pendrak ML, et al. Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci Rep [Internet]. 2013;3:1673. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3628113&tool=pmcentrez&rendertype=abstract. Accessed 26 July 2016.
10. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts DD. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem [Internet]. 2007;282:15404-15. Available from: papers3://publication/doi/ 10.1074/jbc.M701638200.
11. Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide [Internet]. 2009;21:52-62. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1089860309000731. Accessed 26 July 2016.
12. Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, DeGraff WG, et al. Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol [Internet]. 2008;173:1100-12. Available from: http://linkinghub.elsevier.com/retrieve/pii/S000294401061499X. Accessed 26 July 2016.
13. Zhang X, Galardi E, Duquette M, Lawler J, Parangi S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res [Internet]. 2005;11:5622-30. 2005/08/03 ed. Department of Surgery and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16061881. Accessed 26 July 2016.
14. Belmadani S, Bernal J, Wei CC, Pallero MA, Dell'italia L, Murphy-Ullrich JE, et al. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol [Internet]. 2007;171:777-89. 2007/07/21 ed. Department of Physiology and Biophysics, University of Alabama at Birmingham, 668 Volker Hall, 1530 3rd Ave. South, Birmingham, AL 35294-0019, USA. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17640965. Accessed 26 July 2016.
15. Bauer PM, Bauer EM, Rogers NM, Yao M, Feijoo-Cuaresma M, Pilewski JM, et al. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res [Internet]. 2012;93:682-93. 2012/01/05 ed. Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22215724. Accessed 26 July 2016.
16. Labrousse-Arias D, Castillo-González R, Rogers NM, Torres-Capelli M, Barreira B, Aragonés J, et al. HIF-2α-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodelling and vasoconstriction. Cardiovasc Res [Internet]. 2015;cvv243. Available from: http://cardiovascres.oxfordjournals.org/lookup/doi/ Accessed 26 July 2016. 10.1093/cvr/cvv243. Accessed 26 July 2016.
17. Bongrazio M, Da Silva-Azevedo L, Bergmann EC, Baum O, Hinz B, Pries AR, et al. Shear stress modulates the expression of thrombospondin-1 and CD36 in endothelial cells in vitro and during shear stress-induced angiogenesis in vivo. Int J Immunopathol Pharmacol [Internet]. 2006;19:35-48. 2006/03/30 ed. Department of Physiology, Charite Campus Benjamin Franklin--Arnimallee 22, 14195 Berlin, Germany. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16569344. Accessed 26 July 2016.
18. Phelan MW, Forman LW, Perrine SP, Faller DV. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med [Internet]. 1998;132:519-29. 1998/12/16 ed. Cancer Research Center and Department of Medicine, Boston University School of Medicine, MA 02118, USA. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9851743. Accessed 26 July 2016.
19. Kaiser R, Grotemeyer K, Kalsch T, Graber S, Wilkens H, Elmas E. Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction. Clin Hemorheol Microcirc [Internet]. 2013;54:59-73. 2012/07/04 ed. Department of Pulmonology, Saarland University, Homburg/Saar, Germany. ralfkaiser@gmx.net. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22750995. Accessed 26 July 2016.
20. Yao M, Roberts DD, Isenberg JS. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol Res [Internet]. 2011;63:13-22. Elsevier Ltd. Available from: http://dx.doi.org/ 10.1016/j.phrs.2010.10.014. Accessed 26 July 2016.
21. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem. 2010;285:38923-32.
22. Miller TW, Isenberg JS, Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol [Internet]. 2010;159:1542-7. Available from: http://doi.wiley.com/ 10.1111/j.1476-5381.2009.00631.x. Accessed 26 July 2016.
23. Bauer EM, Qin Y, Miller TW, Bandle RW, Csanyi G, Pagano PJ, et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res [Internet]. 2010;88:471-81. 2010/07/09 ed. Vascular Medicine Institute of University of Pittsburgh, Pittsburgh, PA, USA. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20610415. Accessed 26 July 2016.
24. Ochoa CD, Yu L, Al-Ansari E, Hales CA, Quinn DA. Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension. J Cardiothorac Surg [Internet]. 2010;5:32. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. cdo701@jaguar1.usouthal.edu. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20441584. Accessed 26 July 2016.